Plus Therapeutics provided a business update and highlights REYOBIQ clinical progress and CNSide US commercialization. "Our 2 key goals in 2026 are CNSide commercial scale-up and REYOBIQ pivotal trial readiness," said Marc Hedrick, CEO. "Our recently completed upsized $15M offering will fuel faster progress in these core areas of the business and extend our cash runway through 2027." Overview of anticipated company milestones for 2026: REYOBIQ clinical program: Define optimal dose/interval for REYOBIQ in the ReSPECT-LM Phase 2 trial; anticipate reporting data in Q3 2026; Completing enrollment in the ReSPECT-GBM Phase 2 trial for glioblastoma and conduct an end of phase meeting with the FDA to align on pivotal trial design, with data expected in Q4 2026; Complete commercial manufacturing scale up for REYOBIQ; Begin enrollment in the ReSPECT-PBC pediatric brain cancer Phase 1 trial. CNSide commercial roll out: Obtain a total of 150 million US lives covered under multiple commercial payor agreements; Obtain Medicare and Medicaid coverage; Achieve a commercial order rate in excess of 1,250 tests per year; Launch portfolio of additional CSF tumor characterization tests that expand the CNSide testing platform.
Wall Street analysts forecast PSTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSTV is 8.00 USD with a low forecast of 2.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast PSTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSTV is 8.00 USD with a low forecast of 2.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.239
Low
2.00
Averages
8.00
High
19.00
Current: 0.239
Low
2.00
Averages
8.00
High
19.00
Maxim
Maxim
Buy
downgrade
$3
2026-01-23
Reason
Maxim
Maxim
Price Target
$3
AI Analysis
2026-01-23
downgrade
Buy
Reason
Maxim lowered the firm's price target on Plus Therapeutics to $1.50 from $3 and keeps a Buy rating on the shares. The company's ReSPECT-LM Phase 2 dose-optimization study continues to enroll, with data expected in Q3, and following encouraging feedback from its recent Type B meeting with the FDA, Plus plans to advance into a potentially pivotal leptomeningeal metastases study after completion of the current dose-optimization phase, though the firm is adjusting its model to reflect the dilution from the company's recent financing, the analyst tells investors in a research note.
H.C. Wainwright
Sean Lee
Buy
downgrade
$2 -> $1
2026-01-23
Reason
H.C. Wainwright
Sean Lee
Price Target
$2 -> $1
2026-01-23
downgrade
Buy
Reason
H.C. Wainwright analyst Sean Lee lowered the firm's price target on Plus Therapeutics to $1 from $2 and keeps a Buy rating on the shares. The firm cites diluting from the company's recent equity offering for the target cut. It sees a "catalyst-rich" 2026 for Plus Therapeutics.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PSTV
Unlock Now
H.C. Wainwright
Buy
downgrade
$3 -> $2
2025-11-03
Reason
H.C. Wainwright
Price Target
$3 -> $2
2025-11-03
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Plus Therapeutics to $2 from $3 and keeps a Buy rating on the shares. The firm cites dilution associated with the equity raise for the target drop.
D. Boral Capital
Jason Kolbert
Hold
to
Buy
upgrade
$5
2025-09-03
Reason
D. Boral Capital
Jason Kolbert
Price Target
$5
2025-09-03
upgrade
Hold
to
Buy
Reason
D. Boral Capital analyst Jason Kolbert upgraded Plus Therapeutics to Buy from Hold with a $5 price target. The firm, which previously had lowered its rating in May on concerns that the company was likely to execute a reverse split, says it seems those concerns \"may have faded\" for the moment and also cites the progress the company has been making on the diagnostics side. With catalysts such as a diagnostics launch, the firm sees the stock being back up over the \"critical $1.00 mark,\" the analyst added.
About PSTV
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
